Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss
NCT06437054Phase 2Withdrawn
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial of hyaluronic acid in hearing loss (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Analysis of Side Effect Rate through tympanic membrane endoscopy Imaging at 1 week, Analysis of Drug Duration through CT Imaging at 1 week and 1 more. Planned start Dec 2026; status: withdrawn.
02
Drugs
hyaluronic acid
03
Conditions
hearing loss
Beyond the preview
Go deeper on NCT06437054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437054.